Rising Price Target:
Analysts have set a fresh one-year price target for Charles River Laboratories International (NYSE:CRL) at a remarkable 263.39 per share. This represents a substantial 11.10% leap from the previous estimate of 237.07 outlined on January 16, 2024.
This target is a reflection of collective analyst predictions, ranging from a low 214.62 to a soaring high of 304.50. On average, this marks an impressive 6.33% surge from the most recent closing price of 247.71.
Investor Sentiment:
A robust 1339 funds or institutions have reported their stakes in Charles River Laboratories International recently, marking a 1.21% increase in the last quarter. Contrariwise, the average portfolio weight allocated to CRL by all funds is modest at 0.26%, witnessing a slight dip of 2.34%.
Over the past three months, institutional holdings have seen a minor uptick of 0.21%, totaling 67,810K shares. Despite this, the put/call ratio rests at 1.66, indicating a pessimistic outlook prevailing among investors.
Insight into Shareholders:
SMCWX – SMALLCAP WORLD FUND INC retains 5,963K shares, constituting 11.61% ownership of the company, with no changes reported in the last quarter.
Kayne Anderson Rudnick Investment Management’s stake stands at 1,753K shares, representing 3.41% ownership. The firm has shown a notable 0.41% increase in its holdings, juxtaposed against a significant 68.62% reduction in portfolio allocation.
VTSMX – Vanguard Total Stock Market Index Fund Investor Shares hold 1,590K shares, marking a 3.10% ownership. A slight 0.09% increase in holdings contrasts with a 3.16% decrease in portfolio allocation.
On the other hand, AEPGX – EUROPACIFIC GROWTH FUND boasts 1,507K shares, representing 2.93% ownership, without any changes in the last quarter.
Moreover, PRIDX – T. Rowe Price International Discovery Fund retains 1,468K shares, constituting a 2.86% stake, with no recent alterations.
Company Overview:
Charles River Laboratories International plays a vital role in advancing the research and drug development endeavors of pharmaceutical and biotechnology entities worldwide. The company’s unwavering commitment to delivering tailored solutions aids in hastening the discovery, early-stage development, and safe manufacture of novel therapies, ultimately benefitting patients in need of treatment.
(This description is provided by the company.)
Fintel, a leading investing research platform, caters to a diverse audience including individual investors, traders, financial advisors, and small hedge funds. Offering a trove of essential data covering fundamentals, analyst reports, ownership information, and sentiment analysis, Fintel equips its users with the necessary tools to enhance their investment decisions.
For further details, visit Fintel.
Please note that the opinions expressed above are solely those of the author and may not align with the views of Nasdaq, Inc.
